Hormone therapy can make a big difference for men with recurrent or metastatic prostate cancer. But it isn't a cure. Its effects are limited and the side effects can be difficult to cope with.

Metastatic castration-resistant prostate cancer (mCRPC) is a severe form of late-stage disease where the tumor can no longer ...

When prostate cancer has metastasized, and hormone therapy is no longer effective, or when chemotherapy fails or causes ...

ANDROGEN deprivation therapy (ADT) has been the cornerstone of treatment for advanced castration-sensitive prostate cancer ...

Hormone therapy initiation depends on disease extent; some agents avoid testosterone flare, allowing ADT without Casodex in ...

The intended therapeutic effect of gonadotropin-releasing-hormone (GnRH) agonists is hypogonadism, which is a leading cause of osteoporosis in men. Observations are consistent with this effect ...

Opens in a new tab or window In metastatic hormone-sensitive prostate cancer (mHSPC), adding the radioligand 177 Lu-PSMA-617 (Pluvicto) to androgen deprivation therapy (ADT) and chemotherapy more ...

Researchers have found an association between baseline circulating tumor cell count and survival in metastatic ...

Sep. 4, 2024 — A treatment paradox has recently come to light in prostate cancer: blocking testosterone production halts tumor growth in early disease, while elevating the hormone can delay ...

Prostate cancer is Australia's most commonly diagnosed ... delaying the need for hormone therapy or chemotherapy. Stereotactic radiation therapy is delivered daily, with painless radiation beams.

A more advanced form of radiation may be able to treat early and advanced prostate cancers. Here’s how it works and why it ...